ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

ClinicalTrials.gov ID: NCT05422326

Public ClinicalTrials.gov record NCT05422326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59-adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed

Study identification

NCT ID
NCT05422326
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Seqirus
Industry
Enrollment
260 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 17, 2022
Primary completion
Oct 23, 2022
Completion
Mar 23, 2023
Last update posted
May 12, 2026

2022 – 2023

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Optimal Research, LLC Huntsville Alabama 35802
Clinical Research Consortium Arizona Tempe Arizona 85283
California Research Foundation San Diego California 92103
Clinical Research Consulting, LLC Milford Connecticut 06460
Innovative Research of West Florida, Inc. Clearwater Florida 33756
Optimal Research, LLC Melbourne Florida 32934
Great Lakes Clinical Trials LLC Chicago Illinois 60640
Heartland Research Associates, LLC Wichita Kansas 67207
The Center for Pharmaceutical Research Kansas City Missouri 64114
Sundance Clinical Research, LLC St Louis Missouri 63141
Rochester Clinical Research, Inc Rochester New York 14609
PMG Research of Raleigh Raleigh North Carolina 27609
AccellaCare Winston-Salem North Carolina 27103
Aventiv Research Columbus Ohio 43213
Biogenics Research Institute San Antonio Texas 78229
J. Lewis Research, Inc/Foothill Family Clinic North Salt Lake City Utah 84109
J. Lewis Research, Inc/Foothill Family Clinic South Salt Lake City Utah 84121
J. Lewis Research, Inc/Jordan River Family Medicine South Jordan Utah 84095

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05422326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 12, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05422326 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →